Inter-assay and Inter-site Performance of Alpha-Synuclein Seed Amplification Assays in Synucleinopathies: A Multicenter 2×2 Protocol Comparison.
Two different alpha-synuclein tests detect different brain diseases accurately, helping doctors choose the right test for specific synucleinopathy diagnosis.
This multicenter 2×2 cross-assay comparison demonstrates that SPB-SAA and PIPES-SAA conditions have distinct diagnostic profiles: SPB-SAA provides high specificity for PD/DLB but cannot detect MSA, while PIPES-SAA enables MSA detection with good inter-site reproducibility (Kappa 0.913). The findings support context-dependent synSAA selection for synucleinopathy diagnosis — a critical consideration as synSAA moves toward clinical adoption for rare neurological diagnoses.
What the study was
- Study design
- Multicenter 2×2 controlled cross-assay validation study
- Population
- CSF samples from MSA (n=29), PD/DLB (n=16), and neurology controls (n=15)
- Sample size
- 60
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Neurology and Therapy
Why it surfaced
Important multicenter diagnostic validation for synSAA in rare neurodegenerative diseases; confirms inter-site reproducibility but small n=60 limits population generalizability. Directly relevant to rare disease diagnostic standardization.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.